Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing

Annals of Oncology

Volumn 26, Issue 6, 2015, Pages 1216-1223

  Chung, Christine H ^a   Guthrie, V B ^a   Masica, D L ^a   Tokheim, C ^a   Kang, H ^a   Richmon, J ^a   Agrawal, N ^a   Fakhry, C ^a   Quon, H ^a   Subramaniam, R M ^a   Zuo, Z ^b   Seiwert, T ^b   Chalmers, Z R ^c   Frampton, G M ^c   Ali, S M ^c   Yelensky, R ^c   Stephens, P J ^c   Miller, V A ^c   Karchin, R ^a   Bishop, J A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c FOUNDATION MEDICINE   (United States)

Author keywords

Copy number variation; DNA mutation; Head and neck squamous cell carcinoma; Human papillomavirus

Indexed keywords

DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FIXATIVE; FORMALDEHYDE; PARAFFIN; TUMOR MARKER; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER TISSUE; CDKN2A GENE; CDKN2B GENE; CELL CYCLE; COMPARATIVE STUDY; COPY NUMBER VARIATION; DNA SEQUENCE; FEMALE; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC PARAMETERS; GENOMIC ALTERATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRON; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; NOSE CARCINOMA; NOSE CAVITY; OROPHARYNX; OROPHARYNX CARCINOMA; PARANASAL SINUS CARCINOMA; PIK3CA GENE; PRIORITY JOURNAL; PTEN GENE; TP53 GENE; TUMOR GENE; VERY ELDERLY; WART VIRUS; CHEMISTRY; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDY; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; HEAD AND NECK TUMOR; HIGH THROUGHPUT SEQUENCING; HUMAN PAPILLOMAVIRUS DNA TEST; MIDDLE AGED; MUTATION; PAPILLOMAVIRIDAE; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TISSUE FIXATION; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DATABASES, GENETIC; DNA COPY NUMBER VARIATIONS; DNA, VIRAL; FEMALE; FIXATIVES; FORMALDEHYDE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEAD AND NECK NEOPLASMS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; MUTATION; PAPILLOMAVIRIDAE; PARAFFIN EMBEDDING; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TISSUE FIXATION;

EID: 84938090143     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv109     Document Type: Article

References (27)

1. Maier H, Dietz A, Gewelke U et al. Tobacco and alcohol and the risk of head and neck cancer. Clin Investig 1992; 70:320-327.
2. D'Souza G, Kreimer AR, Viscidi R et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944-1956.
3. Bishop JA, Guo TW, Smith DF et al. Human papillomavirus-related carcinomas of the sinonasal tract. Am J Surg Pathol 2013; 37:185-192.
4. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24-35.
5. Rischin D, Young RJ, Fisher R et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28:4142-4148.
6. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100:261-269.
7. Fakhry C, Zhang Q, Nguyen-Tan PF et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 2014; 32:3365-3373.
8. Agrawal N, Frederick MJ, Pickering CR et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333:1154-1157.
9. Stransky N, Egloff AM, Tward AD et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333:1157-1160.
10. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517:576-582.
11. Seiwert TY, Zuo Z, Keck MK et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 2015; 21:870-881.
12. Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31:1023-1031.
13. Mermel CH, Schumacher SE, Hill B et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12: R41.
14. Lechner M, Frampton GM, Fenton T et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV + and HPV-tumors. Genome Med 2013; 5:49.
15. Masica DL, Karchin R. Collections of simultaneously altered genes as biomarkers of cancer cell drug response. Cancer Res 2013; 73:1699-1708.
16. Schaefer CF, Anthony K, Krupa S et al. PID: the Pathway Interaction Database. Nucleic Acids Res 2009; 37: D674-D679.
17. Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome landscapes. Science 2013; 339:1546-1558.
18. Davoli T, Xu AW, Mengwasser KE et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 2013; 155:948-962.
19. Okamoto I, Miyazaki M, Takeda M et al. The tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer. J Thorac Oncol 2015; 10:346-352.
20. Reck M, Kaiser R, Mellemgaard A et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15:143-155.
21. Motzer RJ, Porta C, Vogelzang NJ et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15:286-296.
22. Neskey DM, Osman AA, Ow TJ et al. Evolutionary Action score of TP53 (EAp53) identifies high risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Res 2015 Jan 29 [Epub ahead of print].
23. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9:701-713.
24. Moser R, Xu C, Kao M et al. Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin Cancer Res 2014; 20:4274-4288.
25. Bauman JE, Chung CH. CHK it out! Blocking WEE kinase routs TP53 mutant cancer. Clin Cancer Res 2014; 20:4173-4175.
26. Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck 2012; 34:877-885.
27. Ayiomamitis A, Parker L, Havas T. The epidemiology of malignant neoplasms of the nasal cavities, the paranasal sinuses and the middle ear in Canada. Arch Otorhinolaryngol 1988; 244:367-371.